Research Objectives and Experimental Models The specific goals of a research study dictate the appropriate dosage strategy
Clinical Risk Factors and Pre-Treatment Screening Markers Several risk factors increase gastroparesis susceptibility: diabetes (especially longstanding type 1), vagal neuropathy, autoimmune gastritis, medications affecting motility, and prior gastric surgery
Observational data indicate that metformin causes a rise in fasting and average lactate levels [43], with an average increase (adjusted for plasma glucose and BMI) of 0.16 mmol/l compared with diet or sulfonylurea treatment
If anxiety emerges, your provider can reduce your weekly injection amount, extend your injection interval, or pause treatment for 1-2 weeks while monitoring your nervous system recovery
This table outlines key monitoring milestones and renal markers your provider may track when considering GLP-1 therapy in single-kidney status
For single-dose autoinjectors like Wegovy, Mounjaro, and Zepbound, no bubble removal is needed
